NCT06962800View on ClinicalTrials.gov

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

PHASE3RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

December 29, 2028

Study Completion Date

March 29, 2029

Conditions
Primary Membranous Nephropathy
Interventions
DRUG

Felzartamab

Administered intravenously

DRUG

Tacrolimus

Administered orally

DRUG

Standard of Care IST

Administered intravenously and orally

Trial Locations (4)

10468

NOT_YET_RECRUITING

James J Peters Veterans Administration Medical Center - NAVREF - PPDS, The Bronx

48341

RECRUITING

Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac

90022

RECRUITING

Academic Medical Research Institute, Los Angeles

75231-0929

RECRUITING

Nephrotex Research Group, Dallas

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT06962800 - A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) | Biotech Hunter | Biotech Hunter